Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • March 11th, 2021 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT ("Amendment") is made as of February 25, 2020, by and among C4 Therapeutics, Inc., a Delaware corporation ("C4") and Biogen MA Inc., a Massachusetts corporation ("Biogen").
First Amendment To Amended and Restated license AgreementLicense Agreement • March 11th, 2021 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • England
This First Amendment (the “First Amendment”), effective as of November 12, 2020 (“Amendment Effective Date”) is an amendment to that certain Amended and Restated License Agreement by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, NJ 07424 USA (“Roche US” and, collectively with Roche Basel, “Roche”), on the one hand, and C4 Therapeutics, Inc., with an office and place of business at 490 Arsenal Way, Suite 200, Watertown, MA 02472 (“C4T”) (the “Restated Agreement”). Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Restated Agreement.
